Testing SP-101 gene therapy for cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests a new gene therapy called SP-101 for cystic fibrosis. It aims to see if SP-101 is safe and effective for improving lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old.
- You have a confirmed diagnosis of cystic fibrosis.
- Your lung function (FEV1) is between 50% and 100% of the predicted normal value.
- You have not changed any major lung infection treatments in the last 28 days.
- You have not had gene therapy before.
- You do not have a lung infection with certain hard-to-treat bacteria (Burkholderia cenocepacia or dolosa).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
This trial tests a new inhaled medicine (BMD003) that delivers CFTR mRNA to help correct the genetic defect causing cystic fibrosis. It is for patients who are 12 years or older, have stable CF, and meet certain lung function and weight criteria.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
This study looks at correcting “stop” mistakes (nonsense mutations) in the CFTR gene, which can cause cystic fibrosis. If your CFTR test shows the exact type of mutation the study needs, you may be able to take part.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.